Strata Oncology Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
ANN ARBOR, Mich., May 4, 2021 /PRNewswire/ -- Strata Oncology, Inc. , a precision oncology company advancing molecular indications for cancer therapies, today announced that its abstract on the use of comprehensive genomic and transcriptome profiling to predict the benefit of pembrolizumab in patients with advanced cancer was selected for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually from June 4-8, 2021.
Details of the presentation are as follows:
Additional meeting information is available on the ASCO website, where the abstract will be published on May 19, 2021.
About Strata Oncology
View original content to download multimedia:http://www.prnewswire.com/news-releases/strata-oncology-announces-poster-presentation-at-the-american-society-of-clinical-oncology-asco-annual-meeting-301283400.html
SOURCE Strata Oncology, Inc.